| scholarly article | Q13442814 |
| P50 | author | Selina Luger | Q90053593 |
| Alison Wakoff Loren | Q90758423 | ||
| P2093 | author name string | Jianhua Zhao | |
| Martin Carroll | |||
| Phyllis A Gimotty | |||
| Robert Daber | |||
| Jennifer D Morrissette | |||
| Jing-Mei Hsu | |||
| Alison R Sehgal | |||
| P2860 | cites work | Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1 | Q24316558 |
| The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate | Q24605258 | ||
| Recurring mutations found by sequencing an acute myeloid leukemia genome | Q24634204 | ||
| DNMT3A Mutations in Acute Myeloid Leukemia | Q27559610 | ||
| Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia | Q27851430 | ||
| ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category | Q27851679 | ||
| Prognostic relevance of integrated genetic profiling in acute myeloid leukemia | Q27851726 | ||
| Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). | Q27852247 | ||
| Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study | Q28139696 | ||
| Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461) | Q28209814 | ||
| Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia | Q29615735 | ||
| Mutation in TET2 in myeloid cancers | Q29619292 | ||
| Understanding the limitations of next generation sequencing informatics, an approach to clinical pipeline validation using artificial data sets | Q30757355 | ||
| The role of mutations in epigenetic regulators in myeloid malignancies | Q34033164 | ||
| High-dose daunorubicin in older patients with acute myeloid leukemia | Q34612117 | ||
| Anthracycline dose intensification in acute myeloid leukemia | Q34612121 | ||
| Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia | Q34627568 | ||
| Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia | Q34630212 | ||
| Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia | Q34632784 | ||
| Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association | Q34635511 | ||
| Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia | Q35717852 | ||
| Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications | Q37827283 | ||
| DNMT3a plays a role in switches between doxorubicin-induced senescence and apoptosis of colorectal cancer cells | Q39703300 | ||
| Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. | Q43102402 | ||
| Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study | Q43202683 | ||
| Landmark analysis of DNMT3A mutations in hematological malignancies | Q44744267 | ||
| Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group | Q70753024 | ||
| Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group | Q70891287 | ||
| No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group | Q73021186 | ||
| Treating the elderly patient with acute myelogenous leukemia | Q83217262 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| P304 | page(s) | 1614-1620 | |
| P577 | publication date | 2015-01-21 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia | |
| P478 | volume | 21 |
| Q37109190 | A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia |
| Q26766719 | Acute Myeloid Leukemia: A Concise Review |
| Q39400164 | Acute myeloid leukaemia genomics. |
| Q47432401 | Acute myeloid leukaemia. |
| Q58799268 | Clinical and biological implications of in acute myeloid leukemia with |
| Q91581540 | DNA damage on the DOCK in FLT3-ITD-driven acute myeloid leukemia |
| Q39047646 | DNMT3A in Leukemia. |
| Q37325612 | DNMT3A mutation leads to leukemic extramedullary infiltration mediated by TWIST1 |
| Q30355347 | DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling |
| Q51662748 | Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience. |
| Q39337306 | Epigenetic dysregulation of hematopoietic stem cells and preleukemic state |
| Q26765402 | Epigenetic regulators and their impact on therapy in acute myeloid leukemia |
| Q92154007 | Functional Analysis of DNMT3A DNA Methyltransferase Mutations Reported in Patients with Acute Myeloid Leukemia |
| Q40207115 | Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis |
| Q50061766 | High Expression of TET1 Predicts Poor Survival in Cytogenetically Normal Acute Myeloid Leukemia From Two Cohorts. |
| Q91773870 | Influence of DNMT3A R882 mutations on AML prognosis determined by the allele ratio in Chinese patients |
| Q33925672 | Molecular therapy for acute myeloid leukaemia |
| Q38703904 | Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility. |
| Q43234213 | NPM1 mutation is associated with leukemia cutis in acute myeloid leukemia with monocytic features |
| Q28075654 | Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia |
| Q38428692 | Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics. |
| Q37052890 | Quizartinib elicits differential responses that correlate with karyotype and genotype of the leukemic clone |
| Q51696368 | SETD2 and DNMT3A screen in the Sotos-like syndrome French cohort. |
| Q40195925 | Using "residual" FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience |
| Q53808986 | Utilization of next generation sequencing identifies potentially actionable mutations in chronic lymphocytic leukaemia. |
| Q64059660 | mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy |
Search more.